相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia
Chetasi Talati et al.
HAEMATOLOGICA (2020)
Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people
Gunnar Juliusson et al.
HAEMATOLOGICA (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Christoph Roellig et al.
BLOOD (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
Gunnar Juliusson et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia
Tsila Zuckerman et al.
CURRENT OPINION IN HEMATOLOGY (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
Roland B. Walter et al.
HAEMATOLOGICA (2018)
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
Roland B. Walter et al.
HAEMATOLOGICA (2018)
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Michael R. Savona et al.
CLINICAL CANCER RESEARCH (2018)
Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia
Laura C. Michaelis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia
Chetasi Talati et al.
FUTURE ONCOLOGY (2018)
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
Victoria V. Prassek et al.
HAEMATOLOGICA (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
Victoria V. Prassek et al.
HAEMATOLOGICA (2018)
Geriatric Assessment in Older Patients with Acute Myeloid Leukemia
Kah Poh Loh et al.
CANCERS (2018)
Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort
Jordi Esteve et al.
BLOOD (2018)
Abridged geriatric assessment is a better predictor of overall survival than the Karnofsky Performance Scale and Physical Performance Test in elderly patients with cancer
Marwan Ghosn et al.
JOURNAL OF GERIATRIC ONCOLOGY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H. Metzeler et al.
BLOOD (2016)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Sergio Amadori et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Bruno C. Medeiros et al.
ANNALS OF HEMATOLOGY (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
GAH Scale is a Simple, Comprehensive Assessment Tool in Older Patients With Hematological Malignancies That Shows Mortality Prediction Capacities
J. dela Rubia et al.
Clinical Lymphoma Myeloma & Leukemia (2015)
A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients
Brenda W. Cooper et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
S. Bonanad et al.
JOURNAL OF GERIATRIC ONCOLOGY (2015)
Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia
Heidi D. Klepin
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia
Heidi D. Klepin et al.
BLOOD (2013)
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
Barbara Deschler et al.
HAEMATOLOGICA (2013)
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
A. K. Burnett et al.
LEUKEMIA (2013)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Most 70-to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment
Gunnar Juliusson
BLOOD (2011)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian et al.
BLOOD (2010)
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
Christoph Roellig et al.
BLOOD (2010)
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
Utz Krug et al.
LANCET (2010)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
Anne Etienne et al.
CANCER (2007)
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
Francis J. Giles et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome
H Kantarjian et al.
CANCER (2006)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
The benefit of induction chemotherapy in patients age ≥ 75 years -: A retrospective study of 110 patients from a single institution
N Vey et al.
CANCER (2004)
分享论文
